Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Lymphoid 3Plasma cell 2Genitourinary 2Sarcoma 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × pidilizumab × Lymphoid × Clear all
NCT02530125 2018-03-19

Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission

Northwestern University

Phase 2 Terminated
4 enrolled 8 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00904722 2016-06-03

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
32 enrolled 4 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00532259 2014-09-12

CT-011 MAb in DLBCL Patients Following ASCT

CureTech Ltd

Phase 2 Completed
72 enrolled 9 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡